Product Information
XTAMPZA ER 9 MG CAPSULE is a brand product labeled by Collegium Pharmaceutical, Inc., priced at $6.1057 per EA under NDC 24510011010. Its NADAC has been published 399 times since May 17, 2017.
FDA first approved this application on Apr 26, 2016.
Strength
9 mg/1
Manufacturer
Collegium Pharmaceutical, Inc.NDC
24510011010
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
12/18/2024
Active Ingredients
OXYCODONEApproval Type
New Drug (NDA)
FDA Application
NDA208090FDA Approved
4/26/2016
On Market Since
5/10/2016
Pharmacological Classes
Price Statistics
The NADAC for XTAMPZA ER 9 MG CAPSULE has been published 399 times since May 17, 2017, and over the history we have for it it has risen 76.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.1057 per EA |
|---|---|
| All-time high | $6.1068 (Sep 11, 2024) |
| All-time low | $3.4700 (May 17, 2017) |
| Median price | $5.1553 |
| Average price | $4.9792 |
| Largest weekly change | +9.9% (Jan 9, 2019) |
| Weeks tracked | 399 |
| Tracking since | May 17, 2017 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+2.6%
5Y
+18.4%
All
+76.0%
Last surveyed Jan 1, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the OXYCODONE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Collegium Pharmaceutical, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
OXYCODONE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XTAMPZA ER 9 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for XTAMPZA ER 9 MG CAPSULE, manufactured by Collegium Pharmaceutical, Inc., is $6.1057 per EA (NDC 24510011010), effective Jan 1, 2025.
How has the price of XTAMPZA ER 9 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for XTAMPZA ER 9 MG CAPSULE has risen 76.0%. It has been tracked across 399 weekly CMS publications since May 17, 2017.
What are the highest and lowest recorded NADAC prices for XTAMPZA ER 9 MG CAPSULE?
Since May 17, 2017, the NADAC for XTAMPZA ER 9 MG CAPSULE has ranged from a low of $3.4700 (May 17, 2017) to a high of $6.1068 (Sep 11, 2024), with a median of $5.1553 per EA.
Are there cheaper alternatives to XTAMPZA ER 9 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of XTAMPZA ER 9 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures XTAMPZA ER 9 MG CAPSULE?
XTAMPZA ER 9 MG CAPSULE (NDC 24510011010) is labeled by Collegium Pharmaceutical, Inc., and CMS classifies it as a brand product.